Celladon Corporation Announces Exercise In Full And Closing Of Underwriters' Option To Purchase Additional Shares

SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today the full exercise and closing of the underwriters' option to purchase 825,000 additional shares of common stock in connection with Celladon's previously announced initial public offering of 5,500,000 shares of common stock, at a price to the public of $8.00 per share, bringing the total gross proceeds from the offering to $50.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon. All shares in the offering were sold by Celladon. Celladon's common stock began trading on The NASDAQ Global Market on January 30, 2014 under the symbol "CLDN."

Help employers find you! Check out all the jobs and post your resume.